Ms Deanne Miller (General Counsel, Company Secretary, Chief Op. Officer) ...

Should you invest in Bicara Therapeutics Inc? Click for more on BCAX's promising cancer treatment, but proceed with caution ...

NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, off-the-shelf, immune-modulating therapeutic cancer vaccines based ...

EMA granted clearance to advance belrestotug 400mg + dostarlimab as recommended Phase 3 dose and activate GALAXIES Lung-301 clinical sites in the EU- Interim data from inupadenant Phase 2 A2A-005 in ...

The combination of NUC-3373 plus pembrolizumab was generally well tolerated ... to have two Phase 2 product candidates in our portfolio, each with a distinct mechanism of action, that can potentiate ...

Updated clinical data from VISTA101 presented at SITC 2024.Monotherapy arm fully enrolled and combination arm expected to be fully enrolled by ...

Every product was carefully curated by an Esquire editor. We may earn a commission from these links. Here’s how we test products and why you should trust us.

aDepartment of Hospital Pharmacy, Erasmus University Medical Centre, Rotterdam, Netherlands bDepartment of Medical Oncology, Erasmus University Medical Centre, Rotterdam, Netherlands ...

That’s the worldwide sales figure of a single drug called Keytruda (its generic name is pembrolizumab ... For all cancers, Keytruda’s mechanism of action or the way it works is simple and yet ...